ZUDDAS, ALESSANDRO
 Distribuzione geografica
Continente #
EU - Europa 72.051
NA - Nord America 7.070
AS - Asia 967
OC - Oceania 28
SA - Sud America 13
Continente sconosciuto - Info sul continente non disponibili 3
AF - Africa 1
Totale 80.133
Nazione #
IT - Italia 69.819
US - Stati Uniti d'America 7.012
UA - Ucraina 743
CN - Cina 601
SE - Svezia 481
GB - Regno Unito 298
DE - Germania 232
FI - Finlandia 187
SG - Singapore 166
FR - Francia 137
VN - Vietnam 81
CA - Canada 46
IN - India 35
NL - Olanda 34
AU - Australia 28
RU - Federazione Russa 26
HK - Hong Kong 22
BE - Belgio 17
CH - Svizzera 13
ES - Italia 13
IR - Iran 13
TR - Turchia 12
BR - Brasile 9
KR - Corea 9
IL - Israele 8
NO - Norvegia 8
RO - Romania 8
DK - Danimarca 7
JO - Giordania 6
CR - Costa Rica 5
IE - Irlanda 5
PT - Portogallo 5
MX - Messico 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
EU - Europa 3
JP - Giappone 3
PK - Pakistan 3
PL - Polonia 3
AT - Austria 2
CL - Cile 2
CZ - Repubblica Ceca 2
EC - Ecuador 2
GR - Grecia 2
MT - Malta 2
SM - San Marino 2
AL - Albania 1
BD - Bangladesh 1
BZ - Belize 1
DO - Repubblica Dominicana 1
EE - Estonia 1
LV - Lettonia 1
MD - Moldavia 1
MU - Mauritius 1
PA - Panama 1
SI - Slovenia 1
Totale 80.133
Città #
Cagliari 67.716
Fairfield 921
Woodbridge 846
Chandler 596
Houston 568
Ashburn 460
Ann Arbor 444
Jacksonville 390
Wilmington 384
Seattle 348
Nyköping 342
Cambridge 293
Boardman 193
Rome 184
Milan 176
Boston 141
Nanjing 120
Dearborn 112
Beijing 82
Dong Ket 80
Helsinki 71
San Diego 61
Singapore 61
Shanghai 55
Redwood City 53
Shenyang 45
Charleston 40
Padova 40
Nanchang 38
Verona 34
Guangzhou 29
Turin 28
Bari 27
Changsha 27
Hebei 27
Sassari 27
Toronto 27
Jiaxing 25
Norwalk 25
New York 24
London 23
Washington 22
Florence 20
Orange 20
Tianjin 20
Jinan 18
Pune 17
Auburn Hills 16
Ningbo 16
Naples 15
Palermo 15
Los Angeles 14
Sydney 14
Zhengzhou 14
Falls Church 12
Torino 12
Atlanta 11
Bologna 11
Brescia 11
Brussels 11
Catania 11
Mountain View 11
Saint Petersburg 11
Genoa 10
Nuremberg 10
Redmond 10
Vicenza 10
Chicago 9
Kunming 9
Frankfurt am Main 8
Parma 8
Venice 8
Busto Arsizio 7
Casale Monferrato 7
Castelverde 7
Faenza 7
Fidenza 7
Montepulciano 7
Monza 7
Pescara 7
Pisa 7
Rimini 7
Venezia 7
Amman 6
Amsterdam 6
Borås 6
Casavatore 6
Central 6
Hangzhou 6
Livorno 6
Manchester 6
Mumbai 6
Phoenix 6
Sesto San Giovanni 6
Taizhou 6
Abingdon 5
Ancona 5
Aprilia 5
Augusta 5
Azor 5
Totale 75.761
Nome #
Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder 1.459
Prospective observational study protocol to investigate long-term adverse effects of methylphenidate in children and adolescents with ADHD: The Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study 1.328
Child and Adolescent Behavior Inventory (CABI): Standardization for age 6-17 years and first clinical application 1.229
Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence 1.221
Cognitive Function of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate 1.210
Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine 1.188
Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis 1.186
Cognitive training for attention-deficit/hyperactivity disorder: Meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials 1.160
null 1.153
Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder 1.120
Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives 1.105
Development and psychometric properties of the Suicidality: Treatment Occurring in Paediatrics (STOP) Suicidality Assessment Scale (STOP-SAS) in children and adolescents 1.100
Effects of methylphenidate on height in ADHD children. The monitoring of bone age within the ADDUCE project 1.068
null 1.045
Supplementation with polyunsaturated fatty acids (PUFAs) in the management of attention deficit hyperactivity disorder (ADHD) 1.001
Reports of Perceived Adverse Events of Stimulant Medication on Cognition, Motivation, and Mood: Qualitative Investigation and the Generation of Items for the Medication and Cognition Rating Scale 996
null 980
Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe 977
Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder 954
ADHD management during the COVID-19 pandemic: guidance from the European ADHD Guidelines Group 953
Re-thinking treatment targets in child and adolescent psychiatry 927
Corrigendum: Child and adolescent behavior inventory (CABI): A new instrument for epidemiological studies and pre-clinical evaluation 907
Effects of long-term methylphenidate use on growth and blood pressure: Results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS) 875
ADHD and hyperkinetic disorder 869
The Italian autism network (ITAN): A resource for molecular genetics and biomarker investigations 769
null 754
null 749
Psychosocial risk factors for suicidality in children and adolescents 734
Pediatric acute-onset neuropsychiatric syndrome: A data mining approach to a very specific constellation of clinical variables 700
null 699
null 688
null 675
null 665
null 658
null 632
Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies 617
null 603
CRS-R. Conners’ Rating Scales. Revised. Manuale 602
null 595
null 588
Erratum to: Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: A systematic review of head-to-head studies[ BMC Psychiatry. (2013)13, 237] 585
null 581
null 581
null 568
null 564
null 549
null 536
Prevalence and correlates of mental disorders among adolescents in Italy: The PrISMA Study 526
null 519
null 517
null 506
null 501
null 501
Artificial neural networks analysis of polysomnographic and clinical features in pediatric acute-onset neuropsychiatric syndrome (Pans): From sleep alteration to “brain fog” 498
null 497
null 491
Metabolomic Characterization of Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) 478
null 477
null 467
1H-NMR-Based Metabolomics in Autism Spectrum Disorder and Pediatric Acute-Onset Neuropsychiatric Syndrome 457
null 444
null 428
null 400
null 399
Unbalanced risk-benefit analysis of ADHD drugs – Authors' reply 392
null 379
null 378
A neurodevelopment approach for a transitional model of early onset schizophrenia 376
null 355
The pharmacological treatment of aggression in children and adolescents with conduct disorder. Do callous-unemotional traits modulate the efficacy of medication? 350
A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents 345
Increased Response-Time Variability Across Different Cognitive Tasks in Children With ADHD 342
Neuropsychological characterization of aggressive behavior in children and adolescents with cd/odd and effects of single doses of medications: The protocol of the matrics_wp6-1 study 339
Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study 336
Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis 334
null 334
A crucial role for basic emotion awareness in the development of emotion regulation? 330
The MTA at 8 325
The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD Guidelines Group (EAGG) 324
Use of atomoxetine in patients with attention-deficit hyperactivity disorder and comorbid conditions 323
Profili cognitivi e disturbi psicopatologici. Evidenze neurobiologiche, diagnosi, trattamento 319
Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis 316
null 314
Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial 305
Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trial 304
Omega-3/6 supplementation for mild to moderate inattentive ADHD: a randomised, double-blind, placebo-controlled efficacy study in Italian children 300
The poor outcome of conduct disorders: a need for innovative, more effective therapeutic interventions 299
null 294
Systematic Review and Meta-analysis: Screening Tools for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents 293
Co-release of dopamine and noradrenaline from noradrenergic neurons in the cerebral cortex: implication for the neurobiology of psychiatric disorders 286
Identifying Neurobiological Markers in Obsessive–Compulsive Disorder: A Study Protocol for a Cross-Sectional Study in Subgroups of Differing Phenotype 281
European clinical guidelines for hyperkinetic disorder - first upgrade 281
null 280
Non-pharmacological interventions for Attention-Deficit/Hyperactivity Disorder: Systematic review and meta-analyses of randomised controlled trials of dietary and psychological treatments 270
The Italian preadolescentmental health project (PrISMA): rationale and methods 257
Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design 257
Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder 250
I Disturbi depressivi in età evolutiva 249
Clinical characteristics, neuroimaging findings, and neuropsychological functioning in attention-deficit hyperactivity disorder: Sex differences 249
Association of Risk of Suicide Attempts With Methylphenidate Treatment 247
Totale 60.022
Categoria #
all - tutte 114.826
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 114.826


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019356 0 0 0 0 0 0 0 0 0 0 0 356
2019/202012.007 908 302 102 501 3.549 2.340 1.909 538 444 340 479 595
2020/202116.858 777 510 925 3.862 3.262 1.867 1.869 953 511 590 483 1.249
2021/20227.717 573 518 324 892 763 432 371 602 813 872 740 817
2022/202314.642 1.096 1.876 1.615 1.119 1.080 1.161 683 1.973 984 874 1.515 666
2023/202416.530 834 685 636 1.068 1.981 2.656 2.826 1.023 853 1.235 1.807 926
Totale 80.600